Table 2 Correlations of PD-L1 expression and clinicopathologic characteristics
Positive, n (%) | Negative, n (%) | p-value | |
|---|---|---|---|
Age | |||
≤ 65 years | 8 (50) | 8 (50) | |
> 65 years | 8 (57) | 6 (43) | 0.834 |
Gender | |||
Female | 13 (52) | 12 (48) | |
Male | 4 (80) | 1 (20) | 0.513 |
Karnofsky performance status | |||
90–100% | 8 (80) | 2 (20) | |
70–80% | 8 (40) | 12 (60) | 0.023 |
UICC stage | |||
III | 15 (56) | 12 (44) | |
IV | 1 (33) | 2 (67) | 0.447 |
T category | |||
1–2 | 4 (67) | 2 (33) | |
3–4 | 12 (50) | 12 (50) | 0.073 |
N category | |||
0–1 | 2 (67) | 1 (33) | |
2–3 | 14 (52) | 13 (48) | 0.402 |
Histology | |||
Squamous cell carcinoma | 9 (60) | 6 (40) | |
Non- Squamous cell carcinoma | 7 (47) | 8 (53) | 0.864 |
Tobacco consumption (PY) | |||
0 | 5 (63) | 3 (38) | |
20–40 | 3 (38) | 5 (63) | |
> 40 | 8 (57) | 6 (43) | 0.105 |
Grading | |||
Moderately differentiated | 1 (50) | 1 (50) | |
Poorly differentiated | 14 (54) | 12 (46) | |
anaplastic | 1 (50) | 1 (50) | 0.223 |
CD8+ TILs density | |||
≤ 40% | 5 (50) | 5 (50) | |
> 40% | 10 (59) | 7 (41) | 0.020 |